At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
In Brief
A Phase 2 clinical trial evaluating Nitrous Oxide 25%, Nitrous Oxide 50%, and 1 other intervention for Depressive Disorder, Major and Depressive Disorder, Treatment-Resistant. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
Study Details
Timeline
Interventions
Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.